Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma M&A announcement today. The $132-per-share agreement comes a few months ...
Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a phase 3 trial. Caplyta ...
Abstract: Inter- and intra-chiplet interconnection networks play a vital role in the operation of many core systems made of multiple chiplets. However, these networks are susceptible to faults caused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results